The Present and FutureState-of-the-Art ReviewExtracorporeal Ultrafiltration for Fluid Overload in Heart Failure: Current Status and Prospects for Further Research
Central Illustration
Key Words
Abbreviations and Acronyms
Cited by (0)
Dr. Costanzo served as principal investigator for AVOID-HF trial; has received research support through her institution for the AVOID-HF trial; consultant for Axon Therapies. Columbia University is the assignee for biomarker patents developed by Dr. Barasch. Dr. Fonarow has received funding from National Institutes of Health; and is consultant for Amgen, Janssen, Medtronic, Novartis, and St. Jude Medical. Dr. Gottlieb has received research grants from Amgen and Novartis; and is consultant for Bristol-Myers Squibb. Dr. Levin holds equity in Coridea and Axon Therapies. Dr. Negoianu is a speaker for Gambro Inc./Baxter and Fresenius; and was a member of the Steering Committee for AVOID-HF trial. Dr. Voors has received research grants and consultancy fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Cardio3Biosciences, GlaxoSmithKline, Merck/MSD, Novartis, Servier, Sphingotec, Stealth Peptides, Trevena, and Vifor. Dr. Stough was funded by Coridea, LLC. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.